World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
24959
World Ranking
16107
National Ranking
842

Overview

Bernd Dörken is affiliated with Charité - University Medicine Berlin in Germany. Their research spans several interconnected fields within biomedical science, with a focus on both clinical and molecular aspects of disease.

The main fields of study explored by Dörken include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Dörken's work also extends into specialized subfields such as:

  • Hematology
  • Molecular Biology
  • Oncology

The scientist addresses multiple research topics, particularly within cancer biology and treatment, including:

  • Acute Myeloid Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Histone Deacetylase Inhibitors Research
  • Cancer-related Molecular Pathways
  • Pancreatic and Hepatic Oncology Research
  • RNA modifications and cancer

Dörken has contributed to recent publications, including:

  • "Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study," 2023, Annals of Hematology
  • "Withdrawal: p14ARF induces G2 cell cycle arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity," 2023, Journal of Biological Chemistry

The scientist often collaborates with other researchers in their field. Frequent co-authors include:

  • Dietger Niederwieser
  • Thomas Lang
  • Rainer Krahl
  • Thomas Heinicke
  • Georg Maschmeyer

Dörken's publications have appeared primarily in the following venues:

  • Annals of Hematology
  • Journal of Biological Chemistry

Best Publications

  • Oncogene-induced senescence as an initial barrier in lymphoma development

    Melanie Braig;Soyoung Lee;Christoph Loddenkemper;Cornelia Rudolph

  • Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

    Volker Diehl;Jeremy Franklin;Michael Pfreundschuh;Bernd Lathan

  • Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

    Andreas Engert;Annette Plütschow;Hans Theodor Eich;Andreas Lohri

  • Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

    R C Bargou;F Emmerich;D Krappmann;K Bommert

  • Clinical Experiences with Magnetic Drug Targeting: A Phase I Study with 4′-Epidoxorubicin in 14 Patients with Advanced Solid Tumors

    Andreas Stephan Lübbe;Christian Bergemann;Hanno Riess;Folke Schriever

  • Senescence-associated reprogramming promotes cancer stemness

    Maja Milanovic;Dorothy N. Y. Fan;Dimitri Belenki;J. Henry M. Däbritz

  • Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

  • Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

    Jan R. Dörr;Yong Yu;Maja Milanovic;Gregor Beuster

  • Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma

    Franziska Jundt;Ioannis Anagnostopoulos;Reinhold Förster;Stephan Mathas

  • Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

    Uwe Pelzer;Ingo Schwaner;Jens Stieler;Mathias Adler

  • Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

    Rami Rahal;Mareike Frick;Rodrigo Romero;Joshua M Korn

  • Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma

    Björn Lamprecht;Korden Walter;Stephan Kreher;Stephan Kreher;Raman Kumar

  • PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

    Matthias Pfeifer;Michael Grau;Dido Lenze;Sören-Sebastian Wenzel

  • Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines

    Stephan Hailfinger;Hendrik Nogai;Christiane Pelzer;Maike Jaworski

  • Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)

    Stephan H.K. Oertel;Erik Verschuuren;Petra Reinke;Kristin Zeidler

  • Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells.

    Franziska Jundt;Kristina Schulze Pröbsting;Ioannis Anagnostopoulos;Gwendolin Muehlinghaus

  • CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

    Marianne Sinn;Marcus Bahra;Torsten Liersch;Klaus Gellert

  • Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

    T D Kim;D Rea;M Schwarz;P Grille

  • Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice.

    R C Bargou;C Wagener;K Bommert;M Y Mapara

  • Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma

    Stephan Mathas;Martin Janz;Martin Janz;Franziska Hummel;Michael Hummel

Frequent Co-Authors

Peter T. Daniel
Peter T. Daniel Max Delbrück Center for Molecular Medicine
Michael Hummel
Michael Hummel Charité - University Medicine Berlin
Ioannis Anagnostopoulos
Ioannis Anagnostopoulos Charité - University Medicine Berlin
Harald Stein
Harald Stein Charité - University Medicine Berlin
Thomas Blankenstein
Thomas Blankenstein Max Delbrück Center for Molecular Medicine
Martin Lipp
Martin Lipp Max Delbrück Center for Molecular Medicine
Christoph Loddenkemper
Christoph Loddenkemper Charité - University Medicine Berlin
Claus Scheidereit
Claus Scheidereit Max Delbrück Center for Molecular Medicine
Petra Reinke
Petra Reinke Berlin-Brandenburger Centrum für Regenerative Therapien

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA can also mean exploring alternative pathways and online programs. Many students start by earning a nursing degree, as becoming a Registered Nurse (RN) remains a popular entry route. For those looking to advance quickly and affordably, researching what is the cheapest rn to bsn program online can help minimize costs without sacrificing quality.

If you hold a non-nursing bachelor’s degree but wish to enter advanced practice nursing, direct entry msn programs allow a faster transition, making it possible to enter the field with flexibility and minimal prerequisites.

Those concerned about admissions difficulty can consider nursing programs with high acceptance rates, which offer more accessible entry points and can help open doors to a healthcare career.

Healthcare isn’t limited to clinical roles—fields like medical billing and coding are also in high demand. There are options for individuals seeking administrative careers, with many accredited programs offering financial support, as detailed in financial aid for medical billing and coding.

Best Scientists Citing Bernd Dörken

Trending Scientists